Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06295471 · ClinicalTrials.gov registry record · NA
A Comparative Clinical Study to Assess Pain Score and Wound Healing Following Fractional Ablation With a DFG Laser and CO2 Laser
A NA study of Healthy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT06295471: Recruiting NA study of Healthy, sponsored by Massachusetts General Hospital.
NCT06295471 is a NA study of Healthy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 23 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06295471, a NA study of Healthy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims assess whether the Difference Frequency Generation (DFG) laser could be a better alternative to the CO2 laser in terms of reduced side effects and patient downtime.
Primary Outcome
Subjects will report pain score using VAS for the CO2 and DFG laser treated areas at Visit 1. The VAS is a 10cm long scale with 0cm representing "no pain" and 10cm representing "worst possible pain".
Conditions Studied
Interventions
- DEVICE DFG Laser
- DEVICE CO2 Laser
- DEVICE Optical coherence tomography (OCT)
Study Locations (1)
Massachusetts
- MGH Clinical Unit for Research Trials & Outcomes in Skin - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT06295471 shows while recruiting
NCT06295471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which DFG Laser is the first listed.
NCT06295471 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06295471 about?
NCT06295471 is a clinical study titled "A Comparative Clinical Study to Assess Pain Score and Wound Healing Following Fractional Ablation With a DFG Laser and CO2 Laser". This research study aims assess whether the Difference Frequency Generation (DFG) laser could be a better alternative to the CO2 laser in terms of reduced side effects and patient downtime.
What is the current status of trial NCT06295471?
This trial is currently recruiting. It is a NA study. The enrollment target is 23 participants. The study started on 2024-10-16. Estimated completion is 2026-03.
What conditions does trial NCT06295471 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06295471?
The interventions under investigation include: DFG Laser (DEVICE), CO2 Laser (DEVICE), Optical coherence tomography (OCT) (DEVICE).
Who is sponsoring clinical trial NCT06295471?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06295471 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06295471's enrollment target sits among peer trials
23 838th of 1090 higher than 248 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI